Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Pulmonary arterial hypertension is a rare--albeit deadly--disease that affects the arteries of the lung. In PAH, abnormal growth of cells of the vascular media--or the elastic wall--of the pulmonary arteries, called pulmonary arterial smooth muscle cells, results in thickening of the walls.
Pulmonary arterial hypertension (PAH) is an insidious disease. Symptoms may begin slowly, and even before they appear, extensive damage has caused the obstruction of small arteries leading to increased blood pressure in the lungs.
Pulmonary hypertension is a serious problem associated with a wide variety of lung diseases, which can lead to right ventricular dysfunction and death.
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is supporting Professor Sachin Gupte, a pharmacologist at the New York Medical College, in his endeavours to find a drug treatment for the lung damage that can result from Covid-19 infection.
Andrea Amelse knows hand-washing.
APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated clinical trial with APN01, a recombinant human angiotensin-converting enzyme 2, to treat patients with severe coronavirus infection in the People's Republic of China.
A team of researchers has found that the microflora of bacteria within the gut of humans could be a contributor to the development of pulmonary arterial hypertension (PAH). The study titled, "Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension," in the latest issue of the American Heart Association's journal Hypertension.
Researchers have identified a distinct collection of bacteria found in the gut that may contribute to and predict the development of pulmonary arterial hypertension, according to new research published today in the American Heart Association's journal Hypertension.
Dr. Sudeep Taksali, an orthopedic surgeon, became worried that his 8-year-old daughter had already grown taller than his 12-year-old son. And sometimes she had an attitude more befitting a teenager. Something seemed wrong.
In pulmonary arterial hypertension, high blood pressure in the lungs' arteries causes the heart to work extra hard to pump blood to the lungs and around the rest of the body.
AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.
High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
Scientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension, a severe, often fatal condition that has no cure.
Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation, a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.
New University of Alberta research is paving the way for the first medical treatment to help protect people from cardiovascular disease by boosting the body's natural defenses.
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre-treated with off-label selective vasodilator drugs, according to new research published in Circulation: Heart Failure, an American Heart Association journal.
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
Novel studies from around the world showing cutting-edge clinical use of cardiovascular magnetic resonance will be presented at EuroCMR 2019, a meeting of the European Association of Cardiovascular Imaging, a branch of the European Society of Cardiology.
Trio Health today announced the launch of the TH-PAH database for patients with Pulmonary Arterial Hypertension.